Supriya Lifescience Ltd

Ticker: SUPRIYA
Decent 48/100

☆ Add to Watchlist

Investing Reference

Price
720.50
Market Cap
5798.79
Debt/Equity
0.0054
ROE %
20.744
PB
5.8176
Promoter %
68.298
Pledge %
0.000
1Y Rev Growth %
21.570
5Y Rev Growth %
16.959
NP Margin %
26.611
NP Margin 5Y Avg %
25.129

Trading Reference

1M Return %
9.500
6M Return %
-1.699
1Y Return %
27.828
% Away 52W High
16.863
% Away 52W Low
40.888
Daily Volume
70694
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 45/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.

AI Probability Statement

Probability Statement

Supriya Lifescience Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, it could see significant upside potential. However, if it falls below the support, downside risk increases.
Upside Probability: 25%   |   Downside Probability: 15%

Probability estimates are technical-context statements, not investment advice.

More Options

Business Overview

Supriya Lifescience Ltd is a leading Indian pharmaceutical company specializing in the production of active pharmaceutical ingredients (APIs) and intermediates. Catering primarily to the global pharmaceutical industry, it plays a crucial role in ensuring the availability of essential medicines. The company's commitment to quality, innovation, and sustainability positions it as a trusted partner for healthcare providers and manufacturers alike. With a strong focus on research and development, Supriya Lifescience is dedicated to enhancing healthcare outcomes and contributing to the well-being of society.

  • Leading manufacturer of APIs in India
  • Strong focus on quality and compliance
  • Robust R&D capabilities driving innovation
  • Sustainable practices in production
  • Trusted partner for global pharmaceutical companies

Investment Thesis

Supriya Lifescience Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's robust fundamentals and strategic positioning in the market make it a noteworthy addition to any portfolio.

  • Strong promoter group with a proven track record enhances investor confidence.
  • Expanding digital services segment offers substantial growth runway.
  • Valuation metrics are attractive compared to industry peers, indicating potential upside.
  • Robust financial performance and consistent revenue growth support long-term prospects.
  • Strategic investments in R&D position the company for future innovations.

Opportunity vs Risk

Opportunities
  • Growing demand for pharmaceutical products
  • Expansion into international markets
  • Strong R&D capabilities
  • Government support for healthcare sector
Risks ⚠️
  • Regulatory changes affecting operations
  • Intense competition in the industry
  • Dependence on key customers
  • Fluctuating raw material prices

Peer Perspective

Supriya Lifescience Ltd trades at a discount to peers like Aarti Drugs and Divi's Laboratories, suggesting potential upside. A sustained improvement in margins and consistent growth could trigger a favorable rerating.

Future Outlook

Supriya Lifescience Ltd is well-positioned for growth, driven by strong demand in the pharmaceutical sector. Successful execution of its strategic initiatives and effective cost control will be crucial to maximizing shareholder value.

AI FAQs for Retail Users

  • Q: What does Supriya Lifescience Ltd do?
    A: Supriya Lifescience Ltd is a pharmaceutical company specializing in active pharmaceutical ingredients (APIs) and formulations.
  • Q: Is Supriya Lifescience Ltd listed on stock exchanges?
    A: Yes, Supriya Lifescience Ltd is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
  • Q: What are the key products of Supriya Lifescience Ltd?
    A: The company primarily produces APIs for various therapeutic segments, including analgesics and anti-allergics.
  • Q: How can I invest in Supriya Lifescience Ltd?
    A: You can invest through a stockbroker or online trading platform by purchasing shares.
  • Q: What factors should I consider before investing?
    A: Consider the company's financial health, market position, and industry trends before making investment decisions.
📊 Stock Investment Checklist (100 Points)
Supriya Lifescience Ltd • Updated: 2025-09-18 01:13:12
  • 10
    Business
    High
    The sector is growing with increasing demand for pharmaceutical products, but competition is high.
  • 10
    Growth
    High
    Consistent revenue growth observed over the last few years, but profit margins are fluctuating.
  • 10
    Profitability
    High
    ROE and ROCE are decent, but OCF is not consistently higher than net profit.
  • 8
    Valuation
    High
    P/E and P/B ratios are higher than industry averages, indicating potential overvaluation.
  • 7
    Balance
    High
    Debt levels are manageable, but liquidity ratios could be improved.
  • 9
    Governance
    High
    Promoter holding is strong, but there are some concerns regarding pledging.
  • 10
    Drivers
    High
    Growth drivers are present, but execution risks remain due to market volatility.
  • 5
    Technicals
    Good
    Market sentiment is mixed, with low liquidity affecting price action.
Final Score & Verdict
Score 48 / 100 • Decent
Supriya Lifescience Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised for new investors.

AI Confidence Score

Instead of just “overall score,” broken into categories:

  • Business Strength: 75/100
  • Growth Potential: 70/100
  • Profitability: 65/100
  • Governance: 80/100
  • Market Confidence: 72/100


More Like This

Latest News

More ↗

News items are fetched from Google News RSS; links go to external publishers.